Dec 28 (Reuters) - The U.S. Food and Drug Administration on Wednesday approved TG Therapeutics Inc's drug for patients with relapsing forms of multiple sclerosis, pitting it against rivals from Roche and Novartis, according to the health regulator's website. (Reporting by Sriparna Roy, Khushi Mandowara and Raghav Mahobe in Bengaluru; Editing by Anil D'Silva)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.91 USD | -0.50% | -0.57% | -18.56% |
Apr. 18 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
Apr. 18 | Sector Update: Health Care | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
219.8 CHF | +0.43% | -1.04% | 193B | ||
202.5 USD | +0.23% | +6.27% | 29.48B | ||
89.54 CHF | -0.51% | +4.65% | 201B | ||
13.91 USD | -0.50% | -0.57% | 2.02B | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.56% | 2.02B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.07% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- TGTX Stock
- News TG Therapeutics, Inc.
- U.S. FDA approves TG Therapeutics' multiple sclerosis drug